Comparative Randomized Study of Safety and Immunogenicity of a Non-Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine Versus an RSV Vaccine Adjuvanted with Aluminum Phosphate when Administered Concomitantly with a Licensed Influenza Vaccine in High-Risk Adults Greater than or Equal to 65 Years of Age

Trial Profile

Comparative Randomized Study of Safety and Immunogenicity of a Non-Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine Versus an RSV Vaccine Adjuvanted with Aluminum Phosphate when Administered Concomitantly with a Licensed Influenza Vaccine in High-Risk Adults Greater than or Equal to 65 Years of Age

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2008

At a glance

  • Drugs Influenza virus vaccine; Respiratory syncytial virus vaccine
  • Indications Influenza virus infections; Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2008 Primary endpoint 'Haemagglutin inhibition antibody levels' has been met.
    • 01 Nov 2008 Results published in the Journal of Infectious Diseases.
    • 28 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top